NCT01275859View on ClinicalTrials.gov

Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
Breast Cancer
Interventions
DRUG

Letrozole, Lapatinib

Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks

Trial Locations (1)

138-736

Asan Nedical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER